低中等收入国家类风湿关节炎的经济负担:系统综述与荟萃分析
该系统综述旨在综合类风湿关节炎(RA)对低中等收入国家(LMICs)家庭、卫生系统和社会造成的经济影响。共纳入15项发表于2007至2024年的研究,总样本量218,575名参与者;门诊、住院和医疗费用的汇总年均费用分别为517.72美元(95%CI 3.35-1,032.09)、543.88美元(95%CI 499.51-588.24)和3,379.83美元(95%CI 3,137.58-3,622.08)。结论认为RA在LMICs构成显著经济挑战。
要点
- 纳入15项研究,总样本量218,575名参与者,个体研究样本量62至209,292不等。
- 每患者年均直接费用523至2,837.90美元,间接费用81.80至2,463.40美元。
- 门诊、住院和医疗费用的汇总年均费用分别为517.72、543.88和3,379.83美元。
核心结论
- RA在LMICs构成显著经济挑战,有限的卫生资源和高治疗费用使许多人无法负担照护。
- 本综述独特地强调,改善治疗可及性和优化资源利用可减少医疗和生产力损失,改善患者结局并增强经济韧性。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science和CINAHL等电子数据库,使用与RA和疾病成本相关的关键词。
- 纳入标准为报告RA相关费用、在LMICs进行、以英文发表的研究;使用纽卡斯尔-渥太华量表对队列研究进行质量评价。
- 初筛识别5,134项研究,去除1,028篇重复后,50项研究进行全文审查,最终15项符合纳入标准。
- 纳入研究发表于2007至2024年,涉及土耳其(n=3)、中国(n=2)以及泰国、匈牙利、墨西哥、哥伦比亚、摩洛哥、巴基斯坦、印度、罗马尼亚、巴西和阿根廷各1项。
- 9项研究采用社会视角,6项采用卫生保健视角;总样本量218,575名参与者,个体研究样本量范围为62至209,292。
主要发现
- 每患者年均直接费用范围为523至2,837.90美元,间接费用范围为81.80至2,463.40美元。
- 门诊、住院和医疗费用的汇总年均费用分别为517.72美元(95%CI 3.35-1,032.09)、543.88美元(95%CI 499.51-588.24)和3,379.83美元(95%CI 3,137.58-3,622.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this systematic review was to synthesize the economic impact of rheumatoid arthritis (RA) on households, health systems, and society in low- and middle-income countries (LMICs). METHODS: Electronic databases such as PubMed, Web of Science, and CINAHL were searched using keywords related to RA and cost of illness. Eligible studies were required to report RA-related costs, be conducted in LMICs, and be published in English. Quality appraisal of the included studies was conducted using the Newcastle-Ottawa Scale for cohort studies. A narrative synthesis and meta-analysis of findings was conducted. RESULTS: A total of 5,134 studies was initially identified for screening. After removing 1,028 duplicates, 50 studies were selected for full-text review, and 15 met the eligibility criteria and were therefore included in the review. These studies, published between 2007 and 2024, were conducted in various countries, including Turkey (n = 3), China (n = 2), and one study each from Thailand, Hungary, Mexico, Colombia, Morocco, Pakistan, India, Romania, Brazil, and Argentina. Nine studies adopted a societal perspective, whereas six used a health care perspective. The total sample size was 218,575 participants, with individual study sizes ranged from 62 to 209,292. Average annual direct costs per patient ranged from US$523 to US$2,837.90, and indirect costs ranged from US$81.80 to US$2,463.40. The pooled average annual costs for outpatients, inpatients, and medical costs were US$517.72 (95% confidence interval [CI] $3.35-$1,032.09), US$543.88 (95% CI US$499.51-US$588.24), and US$3,379.83 (95% CI US$3,137.58-US$3,622.08), respectively. CONCLUSION: RA poses a significant economic challenge in LMICs, where limited health care resources and high treatment costs make care unaffordable for many. This review uniquely underscores that enhancing treatment access and optimizing resource use can reduce both medical and productivity losses, improving patient outcomes and strengthening economic resilience.
引用
- Gebrye T, Mbada CE, Fatoye CT, et al. Economic Burden of Rheumatoid Arthritis in Low- and Middle-Income Countries: Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2025. PMID: 40827016. doi:10.1002/acr.25627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。